Jarrett Jennifer 4

What Happened

• Jennifer Jarrett, a director of Zura Bio Ltd (ZURA), was granted a derivative award for 51,000 shares on June 17, 2026. The Form 4 lists the acquisition as a derivative award at $0.00 per share (total $0 reported). This is an equity grant (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-17; Form filed: 2026-06-22 (appears to be filed after the typical 2-business-day Form 4 window).
• Award: 51,000 shares reported as a derivative award at $0.00.
• Shares owned after transaction: Not specified in the information provided in this summary.
• Vesting (footnote): The option vests in twelve substantially equal monthly installments over one year from June 17, 2026. Any remaining unvested portion will vest the day before the next annual shareholders’ meeting, subject to continued service.
• Transaction type: A = Award/Grant (derivative). No immediate cash outlay or sale reported.

Context

• This is a grant of an equity-based award (derivative). The recipient does not receive fully owned common shares until vesting (and may need to exercise the option depending on award terms). Such grants are a common form of director compensation and do not by themselves indicate a buy or sell signal.
• The filing date is later than the usual 2-business-day deadline for Form 4s, which may be noted by investors monitoring insider reporting timeliness.